C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
05 Marzo 2024 - 10:30PM
C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage
biopharmaceutical company dedicated to advancing targeted protein
degradation science, today announced the acceptance of two
preclinical poster presentations at the American Association for
Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10,
2024 in San Diego, California.
Details of the posters are as follows:
Title: CFT1946, a potent, selective BRAF V600X
mutant-specific degrader demonstrates superior activity as a single
agent to clinically approved BRAF inhibitors and standard of care
combinations in preclinical models of BRAF V600X melanoma, CRC,
NSCLC, and brain metastasisAbstract Number:
1658Session Date and Time: Monday April 8, 2024
9:00 AM - 12:30 PM PTLocation: Poster Section
14Session Title: Cell Signaling Components as
Therapeutic TargetsPresenter: Bridget Kreger,
Ph.D., principal scientist, biology
Title: CFT8634, a BRD9 BiDAC™ degrader, is
active in a subset of multiple myeloma cell line models and
synergistic when combined with pomalidomide or
dexamethasoneAbstract Number: 6064Session
Date and Time: Tuesday April 9, 2024 1:30 PM - 5:00 PM
PTLocation: Poster Section 30Session
Title: Targeted Protein
DegradersPresenter: Laura Poling, Ph.D., director,
biology
In November 2023, C4T made the strategic decision to discontinue
clinical development of CFT8634 based on clinical data from the
Phase 1 trial.
About C4 TherapeuticsC4 Therapeutics (C4T)
(Nasdaq: CCCC) is a clinical-stage biopharmaceutical company
dedicated to delivering on the promise of targeted protein
degradation science to create a new generation of medicines that
transforms patients’ lives. C4T is progressing targeted oncology
programs through clinical studies and leveraging its TORPEDO®
platform to efficiently design and optimize small-molecule
medicines to address difficult-to-treat diseases. C4T’s degrader
medicines are designed to harness the body’s natural protein
recycling system to rapidly degrade disease-causing proteins,
offering the potential to overcome drug resistance, drug
undruggable targets and improve patient outcomes. For more
information, please visit www.c4therapeutics.com.
About CFT1946CFT1946 is an orally bioavailable
BiDAC™ degrader designed to be potent and selective against BRAF
V600X mutant targets. In preclinical studies, CFT1946 is active in
vivo and in vitro in models with BRAF V600E-driven disease and in
models resistant to BRAF inhibitors. CFT1946 is currently in a
Phase 1 dose escalation study in BRAF V600 mutant solid tumors
including non-small cell lung cancer, colorectal cancer and
melanoma. More information about this trial may be accessed at
www.clinicaltrials.gov (identifier: NCT05668585).
Contacts:Investors: Courtney SolbergSenior
Manager, Investor RelationsCSolberg@c4therapeutics.com
Media: Loraine Spreen Senior Director, Corporate
Communications & Patient
Advocacy LSpreen@c4therapeutics.com
Grafico Azioni C4 Therapeutics (NASDAQ:CCCC)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni C4 Therapeutics (NASDAQ:CCCC)
Storico
Da Set 2023 a Set 2024